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Abstract
Objective: The objective of the study was to assess urinary biomarkers of renal injury for their individual or collective ability
to predict Worsening renal function (WRF) in patients with acutely decompensated heart failure (ADHF).
Methods: In a prospective, blinded international study, 87 emergency department (ED) patients with ADHF were evaluated
with biomarkers of cardiac stretch (B type natriuretic peptide [BNP] and its amino terminal equivalent [NT-proBNP], ST2),
biomarkers of renal function (creatinine, estimated glomerular filtration rate [eGFR]) and biomarkers of renal injury (plasma
neutrophil gelatinase associated lipocalin [pNGAL], urine kidney injury molecule-1 [KIM-1], urine N-acetyl-beta-D-
glucosaminidase [NAG], urine Cystatin C, urine fibrinogen). The primary endpoint was WRF.
Results: 26% developed WRF; baseline characteristics of subjects who developed WRF were generally comparable to those
who did not. Biomarkers of renal function and urine biomarkers of renal injury were not correlated, while urine biomarkers
of renal injury correlated between each other. Biomarker concentrations were similar between patients with and without
WRF except for baseline BNP. Although plasma NGAL was associated with the combined endpoint, none of the biomarker
showed predictive accuracy for WRF.
Conclusions: In ED patients with ADHF, urine biomarkers of renal injury did not predict WRF. Our data suggest that a weak
association exists between renal dysfunction and renal injury in this setting (Clinicaltrials.gov NCT#0150153).
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Introduction
Numerous clinical studies have shown a strong association
between worsening of renal function (WRF) and mortality in
patients with acutely decompensated heart failure (ADHF)[1].
WRF due to ADHF has been described as cardio-renal syndrome
(CRS), underlying the interaction between cardiac dysfunction
and the risk of renal dysfunction. The role of venous congestion
has received much attention in this setting, which makes
therapeutic interventions to remove fluid suitable to prevent of
treat CRS. Identification of patients with a high risk of WRF
therefore appears warranted in order to select patients who could
best benefit from specific intervention or tailored therapies.
Although baseline renal function and several clinical factors have
been associated with WRF, they remain poorly predictive of WRF.
In this line, identification of clinical and biological markers that
improve diagnostic accuracy and prediction of WRF are needed
[2].
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e112313Table 1. Baseline characteristics of study subjects as a function of the subsequent development of WRF.
Characteristic WRF (N=23) No WRF (N=64) P
Age, years, mean 6 SD 74.6 (10.1) 74.6 (11.7) 0.99
Gender, male, n (%) 16 (69.6%) 9 (60.9%) 0.46
Caucasian, n (%) 23 (100.0%) 57 (89.1%) 0.10
ED Presentation
Chest pain, n (%) 16 (25.0%) 4 (17.4%) 0.46
Paroxysmal nocturnal dyspnea, n (%) 4 (17.4%) 19 (29.7%) 0.25
Orthopnea, n (%) 18 (78.3%) 41 (64.1%) 0.21
Medical History
LVEF, %, mean 6 SD 48.0 (14.7) 55.3 (17.1) 0.15
Chronic kidney disease, n (%) 9 (39.1%) 20 (31.3%) 0.49
Hypertension, n (%) 21 (91.3%) 54 (84.4%) 0.41
Prior heart failure, n (%) 15 (65.2%) 34 (53.1%) 0.32
Myocardial infarction, n (%) 7 (30.4%) 20 (31.3%) 0.94
Coronary artery disease, n (%) 12 (52.2%) 27 (42.2%) 0.41
Peripheral artery disease, n (%) 4 (17.4%) 8 (12.5%) 0.56
Tobacco use, n (%) 12 (52.2%) 34 (53.1%) 0.94
Diabetes mellitus, n (%) 9 (39.1%) 33 (51.6%) 0.31
Concomitant medications
Angiotensin II receptor blocker, n (%) 2 (8.7%) 12 (18.8%) 0.26
Angiotensin converting enzyme inhibitor, n (%) 5 (21.7%) 21 (32.8%) 0.32
Beta blocker, n (%) 16 (69.6%) 48 (75.0%) 0.61
Mineralocorticoid receptor antagonist, n (%) 3 (13.0%) 11 (17.2%) 0.64
Thiazide diuretic, n (%) 5 (21.7%) 6 (9.4%) 0.13
Loop diuretic, n (%) 16 (69.6%) 39 (60.9%) 0.46
Physical Examination
Heart rate, beats/min, mean 6 SD 84.7 (20.9) 88.5 (26.2) 0.49
Systolic blood pressure, mmHg, mean 6 SD 143.1 (32.6) 146.2 (31.2) 0.69
Diastolic blood pressure, mmHg, mean 6 SD 74.6 (19.2) 78.0 (16.7) 0.45
Body-mass index, kg/m2, mean 6 SD 29.4 (7.2) 31.8 (21.0) 0.59
Jugular venous distension, n (%) 11 (47.8%) 27 (42.2%) 0.64
Hepatojugular reflux, n (%) 1 (4.3%) 11 (17.2%) 0.13
Murmur, n (%) 8 (34.8%) 10 (15.6%) 0.05
Rales on lung exam, n (%) 20 (87.0%) 51 (79.7%) 0.44
Cool extremities, n (%) 3 (5%) 0 (0%) 0.29
S3 gallop, n (%) 0 (0.0%) 4 (6.3%) 0.22
Wheezing, n (%) 6 (26.1%) 7 (10.9%) 0.08
Peripheral edema, n (%) 18 (78.3%) 45 (70.3%) 0.46
Chest X Ray
Interstitial edema, n (%) 13 (56.5%) 35 (54.7% 0.88
Pleural effusion, n (%) 14 (60.9%) 19 (29.7%) 0.008
Infiltrate/pneumonia, n (%) 5 (21.7%) 12 (18.8%) 0.76
Laboratory testing
Creatinine, mg/dL, median [IQR] 1.4 (0.9, 1.8) 1.1 (0.9, 1.6) 0.43
BUN, mg/dL, median [IQR] 33.0 (20.0, 43.0) 25.5 (18.5, 38.0) 0.76
eGFR, mL/min/1.73 m2, median [IQR] 45.6 (29.5, 80.4) 60.3 (36.6, 81.3) 0.25
ED management
Intravenous contrast administration, n (%) 2 (8.7%) 6 (9.4%) 0.92
Loop diuretic drip, n (%) 16 (69.6%) 39 (60.9%) 0.46
Initial intravenous furosemide dose, mg, median [IQR] 20.0 (20.0, 40.0) 40.0 (20.0, 40.0) 0.07
Few differences between the groups existed.
doi:10.1371/journal.pone.0112313.t001
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conventional measures of renal function, such as serum creatinine
become abnormal
3. With the development of biomarkers more
specific to renal injury, it may be possible to detect WRF earlier
than such standard means, and thus predict WRF before it occurs.
Although several studies have shown prognostic importance of
several novel biomarkers of renal injury, most have been in
patients with chronic HF [2,4–6]. Few have examined the
outcome measure of WRF [7,8], and even fewer have compared
multiple candidate biomarkers [9]. While the majority of data in
this area has focused on blood-based biomarkers of renal injury,
such as neutrophil gelatinase associated lipocalin (NGAL), the
presence of urine biomarkers (suggested to more specifically
represent renal injury) has not been systematically studied in a
comparative manner.
We conducted a prospective multicenter study, with the aim to
assess the ability of emerging blood and urinary-based biomarkers
of renal injury and function to predict WRF and outcome in
ADHF patients.
Methods
Study design and setting
The Biomonitoring and Cardiorenal Syndrome in Heart
Failure Trial (Clinicaltrials.gov NCT#01570153) enrolled subjects
between April and July 2012 at two tertiary care academic medical
center members of the Global Research on Acute Conditions
Team: the Massachusetts General Hospital (Boston, MA), and
Sant’Andrea Hospital (Rome, Italy). The study was approved by
the Institutional Review Boards at Partners Healthcare and
Sant’Andrea. All patients gave written consent prior to study
procedures using institutionally-approved consent forms.
Selection of Participants
Sequential patients were screened during working hours.
Patients with decompensation of chronic HF as well as new-onset
HF were included. Inclusion criteria included patients with NYHA
Class I–IV symptoms of symptomatic ADHF requiring intensifi-
cation of diuretic therapy. Exclusion criteria included renal failure
requiring current renal replacement therapy, $8 hours from first
dose of intravenous diuretic, and unwillingness or inability to
participate in study procedures.
Methods and Measurements
Baseline demographics, vital signs, and results of physical
examination were recorded after informed consent was signed.
Blood was drawn and urine sample collected and processed as
noted below.
Blood and urine analysis. Blood was drawn into tubes
containing ethylenediaminetetraacetic acid or no anticoagulant,
and spun for 15 minutes; samples were immediately aliquotted to
freezer tubes and frozen at 280u for biomarker measurement
following the completion of the trial. In addition, a 10 mL sample
of urine was collected. If necessary, a urine sample was obtained
from the Foley catheter tube. The urine sample was for
10 minutes, and aliquoted into freezer tubes for biomarkers
measurement following the completion of the trial.
Biomarkers of myocardial stretch included amino-terminal pro-
B type natriuretic peptide (NT-proBNP; Roche Diagnostics,
Indianapolis, IN), BNP (Alere Triage BNP, San Diego CA), and
soluble ST2 (Presage ST2, Critical Diagnostics, San Diego, CA).
Biomarkers of renal function included blood urea nitrogen
(BUN), serum creatinine (Screat), and estimated glomerular
filtration rate (eGFR; estimated using the simplified Modification
of Diet in Renal Disease equation). Biomarkers of renal injury
included plasma NGAL (Alere, San Diego, CA), urinary Cystatin
C (uCyst; Millipore, Billieria, MA), urine fibrinogen (Millipore,
Billieria, MA) and urine N-acetyl-beta-D-glucosaminidase (NAG;
Roche Diagnostics, Basel, Switzerland). In addition, another
marker of renal proximal tubular injury, Kidney Injury Mole-
cule-1 (KIM-1), was measured in the urine using previously
established Luminex-based assay and the levels of all urinary
biomarkers were normalized to urinary creatinine. Urinary
creatinine concentrations were measure using commercially
Table 2. Results of baseline biomarkers in patients who developed worsening renal function and those who did not.
Worsening renal function
Variable Yes (N=26) No (N=76) P
Biomarkers of cardiac stretch
NT-proBNP, pg/mL, median [IQR] 4629 [2320–8620] 3207 [1746–8131] 0.48
BNP, pg/mL, median [IQR] 600 [263–1570] 437 [234–724] 0.20
sST2, ng/mL, median [IQR] 106 [82–182] 101 [69–154] 0.43
Biomarkers of renal function
Screat, mg/L, median [IQR] 1.4 [0.9–1.8] 1.1 [0.8–1.6] 0.21
eGFR, ml/min, median [IQR] 46 [29–80] 60 [37–81] 0.25
Biomarkers of renal injury
NGAL, pg/mL, median [IQR] 233 [149–379] 174 [102–244] 0.13
Urine KIM-1, pg/mL, median [IQR] 963 [182–1547] 681 [208–194] 0.76
Urine NAG, UI/ml, median [IQR] 2.1 [1.1–3.2] 2.4 [1.3–4.1] 0.52
Urine fibrinogen, ng/mL, median [IQR] 46 [14–82] 40 [9–257] 0.76
Urine Cystatin C, ng/mL, median [IQR] 62 [41–114] 97 [34–195] 0.27
Amino-terminal pro-B type natriuretic peptide, NT-proBNP; B type natriuretic peptide, BNP; Estimated glomerular filtration rate, eGFR; Neutrophil gelatinase-associated
lipocalin, NGAL, urine kidney injury molecule-1, KIM-1, urine N-acetyl-beta-D-glucosaminidase, NAG. Urine biomarkers are expressed per gram urinary creatinine.
doi:10.1371/journal.pone.0112313.t002
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were blinded of the results of the biomarkers excepted for NT-
proBNP and BNP, which were typically drawn for the purposes of
standard of care evaluation of HF.
Outcomes
The primary endpoint of the study was the ability of objective
measures to predict WRF defined as a rise of serum creatinine by
an absolute change of 0.3 mg/dL or a relative rise $25% from
baseline within 72 hours from admission. In patients meeting the
criteria of WRF, the etiology of renal dysfunction was judged by
two study physicians blinded to the results of novel renal
biomarkers using standard criteria. Patients with WRF were
subsequently characterized using RIFLE classification.
Analysis
Baseline variables of study participants as a function of WRF
were compared using the students T test or X
2 test as appropriate;
the Mann-Whitney U test was used for continuous variables in the
states of non-normality. Continuous variables were summarized as
mean 6 standard deviation if normally distributed, while non-
normally distributed continuous variables were summarized as
median and inter-quartile range.
Using WRF as the gold standard diagnosis, median biomarker
concentrations were compared. Results from biomarker testing
were examined as a function of RIFLE classification using the
Kruskal-Wallis test. Receiver operating characteristic (ROC) tests
compared the results of each biomarker for predicting WRF,
expressed as area under the ROC. From ROC testing, an optimal
threshold for predicting WRF was identified for candidates.
Univariable comparisons between baseline characteristics were
used to identify candidate variables for entry to a multivariable
logistic regression model; in both uni- and multivariable models,
we used WRF as the dependent variable first, followed by separate
analyses for WRF or in-hospital death; only those with a P value ,
.05 were retained for multivariable modeling. Odds ratios (OR)
and 95% confidence intervals (CI) were generated.
In order to better examine the prognostic importance of
biomarker combinations, subjects were grouped relative to optimal
cut-offs for natriuretic peptides plus NGAL, and again examined
in uni- and multivariable logistic regression. Rates of WRF as a
function of results of candidate predictors were examined.
ROC analyses were performed using Analyse It software (Leeds,
UK), while all other statistical analyses were performed using
either PASW Statistics Version 17.0 (Chicago, IL, USA) or SAS
(Version 9.2; Cary, NC, USA). All P values are two-sided with a
value of ,0.05 considered significant.
Results
Characteristics of study subjects
87 consecutive emergency department patients with ADHF
(mean age 74.6611.5 years) were enrolled with both blood
and urine sample. Of those patients enrolled, 53 (56%) had
decompensation of prior chronic HF. Of these, 23 (26%)
developed WRF. Eight patients died (9.2%) during hospitalization.
Of these, 6 (75%) developed WRF prior to dying. The median
change in renal function among those dying was +39%
(interquartile range 1.0%–82%). Baseline characteristics as a
function of WRF are detailed in Table 1. Demographic
characteristics and clinical presentation did not differ between
patients with and without WRF, except for higher frequency of
pleural effusion on chest radiography among those who later
developed WRF.
Biomarkers to predict outcome
Table 2 details median concentrations of biomarkers in
patients as a function of WRF. Though numerical differences
were seen, no statistical difference was observed when considering
the median values of each biomarker relative to the presence or
absence of WRF. We subsequently dichotomized patients with
biomarkers above or under the median value of the biomarkers to
Figure 1. Receiver operating curve of biomarkers of cardiac
stretch (1A), renal function (1B) and renal injury (1C).
doi:10.1371/journal.pone.0112313.g001
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or without WRF did not differ for all biomarkers of cardiac stretch,
renal function or renal injury.
Results of the ROC curves analysis are presented in Figure 1
and show poor area under the curve for both outcomes examined.
In univariable analyses (Table 3), among biomarkers measured,
only BNP was predictive of WRF. In adjusted analyses, no
biomarkers remained in the model for predicting outcomes.
Relationship between renal injury and renal function
Spearman correlation coefficients are presented in Table 4.
Interestingly, while plasma NGAL and biomarkers of renal
function (BUN and Screat) were correlated, none of the urine
biomarkers of renal injury correlated with biomarkers of renal
function on admission. Urine biomarkers of renal injury exhibited
correlation (but inconsistently) between each other. None of the
urine biomarkers of renal injury correlated with plasma NGAL.
Discussion
Altered renal function and WRF are well-established factors
associated with poor-prognosis in patients with ADHF. Type 1
CRS, defined as an alteration of renal function in consequence of
HF, has therefore been a matter of major interest in trying to
better understand its mechanisms and implication in the course of
HF patients. CRS emerges from the combination of systemic and
intra-renal hemodynamic alterations as well as inflammatory
mechanisms [3]. What challenges clinicians monitoring patients
with ADHF at risk for CRS is the fact that not all WRF is
associated with poor prognosis, and also that the standard tools for
recognizing change in renal function (typically serum creatinine or
eGFR) lags behind the acute insult to the kidney [10,11].
Accordingly, the complex mechanisms for CRS, variable pheno-
types of WRF, and imperfect tools for its diagnosis make new
approaches necessary. Some degree of increase in serum
creatinine and hemoconcentration appear to be associated with
better outcome compared to patients with no increase in serum
creatinine in some observational study. However these observa-
tions appear true only with slight elevation in serum creatinine (,
20%), only reflecting hemoconcentration but not true decline in
GFR. On our cohort, only 3 out of 8 who died had change ,+
20% in Screat. With the development of biomarkers potentially
indicative of renal injury comes the opportunity to potentially
better characterize episodes of WRF, thus providing better
Table 3. Logistic regression analysis for the primary endpoint of WRF.
Variable Univariate OR (95% CI) worsening renal function
P-value worsening renal
function
ST2 1.01 (0.97, 1.06) 0.482
BNP 1.10 (1.01, 1.19) 0.022
SCreat 1.35 (0.82, 2.22) 0.246
eGFR 0.90 (0.75, 1.07) 0.229
NAG 1.02 (0.93, 1.11) 0.699
NGAL 1.12 (0.93, 1.34) 0.238
NT_proBNP 1.03 (0.99, 1.06) 0.157
Log BNP 1.76 (0.99, 3.13) 0.054
Log NGAL 1.60 (0.84, 3.05) 0.153
Log NT-proBNP 1.32 (0.85, 2.06) 0.219
Log ST2 1.46 (0.73, 2.91) 0.282
BNP . median 1.89 (0.71, 5.01) 0.201
Cystatin . median 1.38 (0.53, 3.61) 0.507
Urine fibrinogen . median 0.53 (0.20, 1.41) 0.204
Kim-1 . median 1.09 (0.42, 2.83) 0.858
NAG . median 1.16 (0.45, 3.01) 0.759
NGAL . median 1.89 (0.71, 5.01) 0.201
NT-proBNP . median 1.43 (0.55, 3.77) 0.464
ST2 . median 1.88 (0.71, 4.96) 0.204
BNP .553 ng/ml 2.36 (0.89, 6.27) 0.084
BUN .33 (optimal cut) 2.02 (0.76, 5.34) 0.158
Creatinine .1.35 mg/l
(optimal cut)
2.23 (0.85, 5.89) 0.105
eGFR ,60 ml/min (optimal cut) 1.56 (0.59, 4.10) 0.372
NGAL .196 ng/ml (optimal cut) 1.77 (0.67, 4.69) 0.251
NT-proBNP .2840 ng/ml
(optimal cut)
1.59 (0.59, 4.30) 0.360
In univariable analysis, several candidates were significant predictors. Optimal cutoffs were determined using the value providing optimal sensitivity and specificity
balance. Amino-terminal pro-B type natriuretic peptide, NT-proBNP; B type natriuretic peptide, BNP; Estimated glomerular filtration rate, eGFR; Neutrophil gelatinase-
associated lipocalin, NGAL, urine kidney injury molecule-1, KIM-1, urine N-acetyl-beta-D-glucosaminidase, NAG; urine Cystatin C, uCyst C.
doi:10.1371/journal.pone.0112313.t003
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recognition of on-going renal injury (i.e. renal damage) may help
to anticipate WRF and therefore provide a window for tailored
therapeutic interventions.
In this study we included 87 consequent patients admitted in
two centers with ADHF and simultaneously measured blood based
biomarkers of cardiac function, renal function and renal injury, as
well as urine-based biomarkers of renal injury, including urine
KIM-1, NAG, cystatin C and fibrinogen. The central finding of
our study was that none of the biomarkers of renal function or
renal injury was entirely accurate to predict WRF in this
population. Surprisingly, patients who subsequently developed
WRF did not show worse renal dysfunction or more intense renal
injury on admission than patients who did not. Within this small
group, the only biomarker that identified risk for WRF was BNP,
actually, re-enforcing the role of renal congestion in this setting.
Despite the negative result for WRF, we reproduced findings from
previous studies showing an association between mortality and
renal dysfunction in showing that biomarkers of renal function (i.e.
Screat and eGFR) were predictor of WRF.
NGAL is the biomarker of renal injury that has received most
attention in critically ill patients as well in patients with HF. NGAL
is a member of the lipocalin superfamily of proteins, expressed in
various types of cells (including epithelial cells) freely filtered by the
glomerulus and thenafter reabsorbed by proximal tubular cells
[14]. Plasma NGAL was shown to increase in various conditions
including systemic inflammation, cancer or atherosclerosis. Previ-
ously studies have yielded conflicting results with regard to
predictive accuracy of NGAL in different conditions, including
ADHF patients. While some suggested that pNGAL could predict
WRF with moderate or good accuracy [15]. Others found that
pNGAL [16] was poorly or not predictive of WRF in this setting.
In a single center study, Shrestha et al reported that uNGAL had
lower AUC than pNGAL for prediction of WRF in ADHF
patients [17]. Our results are in the line with results observed in
those studies.
While studies of urinary biomarkers have shown evidence of
renal injury in patients with chronic HF [18,19]. Very few studies
have focused on urinary biomarkers in ADHF. KIM-1 is a type I
transmembrane glycoprotein highly expressed in post-ischemic
kidneys and released after acute kidney injury (AKI). Likewise,
NAG, a lysosomal brush border enzyme of the proximal tubule
cells is released into the urine after renal injury; both may serve as
biomarkers of tubular injury, and both may be more specific for
renal injury due to venous congestion than NGAL. In a
pathophysiologic study, KIM-1 and NAG rapidly increased after
diuretic withdrawal (with parallel BNP increase) while NGAL was
not affected; both urinary peptides returned to baseline values
after reintroduction of diuretic [20]. In a single center study,
uNGAL levels were not different on admission between patients
with renal dysfunction and those without [21]. Shrestha et al found
that uNGAL and pNGAL had similar - but modest - ability to
predict WRF (AUC-ROC of 0.64 and 0.67 respectively) [17].
However, in another single center study including 53 patients,
Park et al found that uNGAL and KIM-1 levels were not higher in
patients with AKI and could not predict recovery from AKI [21].
To the best of our knowledge, our study for the first time explored
the predictive value of urine Cystatin C and urine fibrinogen in
ADHF patients. Cystatin-C 13.3-kDa non-glycosylated cysteine
protease inhibitor produced by all nucleated cells of the body and
released at a constant rate, freely filtered by the glomerulus and
then reabsorbed by the tubular epithelial cells. Cystatin C detected
in the urine is therefore used as a biomarker of tubular dysfunction
and injury [22]. Urine fibrinogen has recently been described as a
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regulated after kidney ischemia/reperfusion in rats and humans
[23]. However, urine fibrinogen was not predictive of WRF or
mortality in our study.
Taken together, consistency of result throughout clinical studies
does not appear to support the use of biomarkers of renal injury to
predict WRF in patients with ADHF. However, our results add to
the evidence that renal injury and renal dysfunction should be
view as separate entities in this setting. Interestingly, none of the
urine biomarkers of renal injury correlated with biomarkers of
renal function, but did show correlations between each other. On
the other hand, biomarkers of renal function did correlate with
blood-based biomarkers of cardiac stretch (i.e. BNP, NT-proBNP,
sST2) and NGAL. Our results suggest patients may have ongoing
kidney damage (with constitutive release of biomarkers of renal
injury) uncoupled from loss of renal function. These data argue
that urine biomarkers provide different type of information that
blood biomarkers in ADHF. Urine biomarker could more
specifically reflect renal injury than blood biomarkers, but may
lack specificity for predicting clinically significant WRF. These
observations may arise from the association between rather limited
renal injury in this setting and the various renal functional reserves
available in those patients. For the same volume of damaged
nephrons, loss of renal function would therefore be more
pronounced in patients with low or no renal functional reserve
compared to patients with intact renal structure and functional
reserve. On the opposite, renal function biomarkers were
correlated with biomarkers of venous congestion and cardiovas-
cular disease. Altogether, these data strongly supports the
contention that WRF in ADHF arises mostly from hemodynamic
factors (i.e. venous congestion) and not from profound structural
damage to the kidney. Hopefully, these studies will provide
additional data to find out whether ADHF-related renal injury
should be viewed as an isolated outcome caused by one
mechanism or a broader syndrome with various management
strategies driven by various clinical or biochemical guides.
Our study suffers from several limitations. First, it was a rather
low sample size with possible lack of power to show a statistical
association between biomarkers and outcome, especially for
mortality. However, increasing the sample size might allow to
reach statistical difference, but such a poor predictive value of
renal injury biomarkers in this setting are very much unlikely to be
relevant to predict WRF from a clinical perceptive (i.e. for the
caring physician on an individual basis for his patient). We believe
that biomarkers of renal injury should be studied for a different
need than to predict WRF in this setting. Still, a large prospective
study is needed for a definitive answer on the prognosis value of
renal injury biomarkers in ADHF and their use to guide
therapeutic interventions [24,25].
Our study was furthermore prospective and designed with a
priori assumptions regarding the endpoints. Notably, we studied a
mixture of patients with both chronic and de novo HF. Given the
potential effects of chronically administered HF therapeutics such
as renin-angiotensin-aldosterone inhibitors on risk for WRF, it
remains unclear if analysis of more pure cohorts with all of one or
the other scenario would provide comparable results. Another
issue are the multiple comparisons performed in this relatively
small dataset increases the risk for Type I or Type II error. While
correction techniques might alleviate this issue, they are not
typically used in such datasets of this size. As well, the overall
consistent directionality of data reduces the potential for incorrect
interpretation. Finally, our study was performed in only two
centers that may limit the generalizability of our results.
Conclusions
In ED patients with ADHF, urine biomarkers of renal injury did
not predict WRF. Our data suggest that a weak association exists
between renal dysfunction and renal injury in this setting.
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